What we do
HQ & Pipeline
Digital Therapeutics
At the core of a sustainable society
are health and well-being, the areas where
Orexo makes its biggest impact.
Key News
MAY 9, 2023
Fentanyl Awareness Day 2023: "Fentanyl is in everything and it’s killing so many people."
APRIL 27, 2023
Orexo Interim Report Q1 2023
APRIL 26, 2023
Presentation of Orexo's Q1 Interim Report 2023 - April 27 at 2 pm
amorphOX® – a versatile drug delivery platform
Orexo’s novel drug delivery platform has unique properties for the development of differentiated pharmaceuticals that need to be absorbed rapidly by the body and remain stable over time.
News Flow
Press Releases & News
Financial Snapshot
Group net revenues
624 MSEK
LTM1
Group EBITDA
-159 MSEK
LTM1
US Pharma segment EBIT
299 MSEK
LTM1
Cash position
279 MSEK
Q1 2023
1 Last Twelve Months, Q222-Q123, for more information about financial development Link
Orexo Social
@OrexoABpubl
1 June 2023
Yesterday CEO Nikolaj Sorensen presented at @ABGSC Life Science Seminar in Sthlm, Sweden. View an excerpt from th… https://t.co/jiXm8elf3R
@OrexoABpubl
31 May 2023
#Orexo is a commercial stage pharma company. At Erik Penser Bank´s Bolagsdag hosted last week our CEO joined a pane… https://t.co/20sInM1Kgr
@OrexoABpubl
31 May 2023
Nu kan du lyssna på presentationen på Erik Penser Banks Bolagsdag som hölls förra veckan. Då ESG-frågor blir allt v… https://t.co/WFVe1isvYr